Rein Therapeutics (RNTX) AI Stock Analysis

• Market Cap: $34.17M
• Dividend Yield: N/A
• Average Volume (3M): 228.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.24
• Revenue Growth: N/A
• EPS Growth: 15.35%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.21
• Shares Outstanding: 26,286,383
• 10 Day Avg. Volume: 262,542
• 30 Day Avg. Volume: 228,948
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $10.00
• Price Target Upside: 693.65% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $1.50 ▲(19.05% Upside)

The score is held back primarily by weak financial performance (no revenue, large losses, and ongoing cash burn) despite low leverage. Technicals are comparatively supportive with the stock trading above key moving averages, while valuation is constrained by continued losses. A positive corporate event (FDA lift of clinical hold and Phase 2 restart) adds upside potential but does not offset the current cash-burn profile.

Positive Factors

Low leverage / minimal debt

Essentially zero debt materially lowers refinancing and interest rate risk over the next 2-6 months, preserving optionality for trial funding and strategic moves. This structural conservatism improves survival odds during clinical development compared with highly leveraged peers.

Regulatory clearance to resume Phase 2

Lifting the clinical hold is a durable operational inflection: it removes a regulatory barrier, enables U.S. enrollment at ~20 sites, and preserves the program's timeline toward topline data in Q3 2026. This materially improves the pipeline's realistic path to value creation.

Access to alternative financing

Ability to raise capital via exempt private note offerings shows the company can secure non-dilutive or flexible funding channels without public equity issuance. Structurally this can extend runway and reduce reliance on volatile public equity markets during clinical development.

Negative Factors

Zero revenue

No commercial revenue is a sustained structural constraint: the business is entirely dependent on external financing and clinical success to ever reach profitability. This leaves cash runway and financing access as primary determinants of long-term viability.

Persistent negative operating and free cash flow

Ongoing multi-period cash burn erodes liquidity and forces repeated capital raises or cost cuts. Structurally worsening FCF magnifies dilution risk, limits ability to fund trials internally, and makes long-term planning contingent on external capital markets or partners.

Erosion of shareholders' equity and negative ROE

Declining book equity and negative ROE indicate accumulated losses are depleting the balance-sheet buffer that protects creditors and funds operations. Over months, this heightens the chance of dilutive financing and reduces strategic flexibility for pipeline advancement.

Rein Therapeutics Business Overview & Revenue Model

Company Description

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

How the Company Makes Money

Rein Therapeutics Financial Statement Overview

Summary

Weak fundamentals driven by zero revenue, sizable ongoing net losses, and persistent negative operating/free cash flow (TTM FCF about -$21.0M). The main offset is a conservatively financed balance sheet with essentially no debt, though equity has been eroding as losses continue.

Income Statement

The company reports no revenue across the annual periods and TTM (Trailing-Twelve-Months), which limits operating leverage and visibility into a path to profitability. Losses have expanded materially in TTM (Trailing-Twelve-Months) (net loss of ~$58.9M vs. ~$62.9M in 2024, still deeply negative), indicating elevated spending relative to the current business scale. While year-to-year comparisons of margins are not meaningful given zero revenue, the persistence of large operating losses is the key weakness; the main strength is simply that losses are being funded without reliance on debt.

Balance Sheet

The balance sheet is conservatively financed with essentially no debt in recent periods (debt-to-equity at 0.0 in TTM and 2024), reducing financial risk and refinancing pressure. Equity remains positive (~$46.2M in TTM vs. ~$54.4M in 2024), but the trend shows erosion in shareholders’ equity as losses accumulate, and returns on equity are sharply negative in TTM (about -2.17), reflecting significant value dilution risk if cash needs persist. Overall, low leverage is a clear strength, offset by weakening equity and poor profitability.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are both negative in every period shown, including TTM (Trailing-Twelve-Months) (about -$21.0M), indicating ongoing cash burn. Free cash flow deterioration is notable in TTM (Trailing-Twelve-Months) (free cash flow growth of roughly -128%), suggesting a worsening near-term burn profile versus the prior base. A modest positive is that cash burn is not being compounded by interest burden given minimal debt, but the core risk remains sustained negative operating and free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-60.59M	-28.05M	-15.23K	-27.48K	-26.48K	-20.33K
Net Income	-58.88M	-62.88M	-15.73K	-27.33K	-26.16K	-21.16K
Balance Sheet
Total Assets	53.71M	69.24M	106.01M	22.01M	48.48M	16.34M
Cash, Cash Equivalents and Short-Term Investments	4.05M	12.87M	17.31M	21.24M	45.93M	13.80M
Total Debt	0.00	0.00	48.00K	33.00K	162.00K	387.00K
Total Liabilities	7.52M	14.85M	99.12M	3.38M	4.58M	4.18M
Stockholders Equity	46.19M	54.39M	6.89M	18.62M	43.90M	12.16M
Cash Flow
Free Cash Flow	-20.95M	-22.29M	-19.81M	-24.86M	-23.91M	-20.48M
Operating Cash Flow	-20.95M	-22.29M	-19.81M	-24.86M	-23.75M	-20.48M
Investing Cash Flow	0.00	0.00	16.20M	26.46M	-35.92M	6.41M
Financing Cash Flow	7.35M	17.82M	15.79M	0.00	55.66M	15.80M

Rein Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNTX, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.28, below the 50-day MA of 1.34, and below the 200-day MA of 1.45, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 48.44 is Neutral, neither overbought nor oversold. The STOCH value of 58.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RNTX.

Rein Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RNTX	53 Neutral	$34.17M	-0.49	-83.28%	―	―	15.35%
KZR	52 Neutral	$44.45M	-0.72	-56.86%	―	―	35.80%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VVOS	43 Neutral	$15.29M	-0.82	-335.47%	―	18.76%	60.09%
OKUR	42 Neutral	$35.77M	-0.43	-115.64%	―	―	46.20%
RANI	41 Neutral	$147.04M	-1.53	―	―	―	25.08%

Rein Therapeutics Corporate Events

Rein Therapeutics Raises Capital via Private Note Offering

Rein Therapeutics disclosed that it sold a note under a Purchase Agreement through a private placement exempt from registration under the Securities Act of 1933, relying on Section 4(a)(2) and Rule 506 of Regulation D for offerings not involving a public offering. The transaction indicates the company is raising capital through exempt securities offerings rather than a public issuance, a move that can provide financing flexibility while limiting disclosure obligations associated with a registered public offering.

The most recent analyst rating on (RNTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.

Rein Therapeutics Ends Key Financial Agreements

On December 11, 2025, Rein Therapeutics, Inc. decided to terminate its Pre-Paid Advance Agreement and Standby Equity Purchase Agreement with YA II PN, Ltd., a Cayman Islands exempt limited partnership. The company had previously received $3 million in advances under the PPA, with the last advance taken on October 23, 2025, but did not sell any common stock under the SEPA. The termination of these agreements did not result in any penalties or fees for the company.

The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.

Rein Therapeutics Resumes Phase 2 Trial for LTI-03

On November 3, 2025, Rein Therapeutics announced that the FDA has lifted the clinical hold on their Phase 2 trial of LTI-03 for idiopathic pulmonary fibrosis, allowing the company to resume U.S. enrollment in late 2025 or early 2026. This clearance is a significant milestone for Rein, as early data suggests LTI-03 may not only slow fibrosis but also promote lung healing, potentially impacting the treatment landscape for IPF. The trial will be conducted across approximately 20 U.S. sites and is part of a broader global study, with initial topline data expected in Q3 2026.

The most recent analyst rating on (RNTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Rein Therapeutics stock, see the RNTX Stock Forecast page.